Lunsumio VELO Has Been Approved for R/R FL

FDA has approved CD20xCD3 bispecific Lunsumio VELO (mosunetuzumab), as a subcutaneous formulation, for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

Study Shows mRNA Vaccine Revitalizes the Immune System

Researchers have demonstrated that weakened immune systems of older individuals can be rejuvenated using mRNA technology to transform the liver in mice into a temporary source of immune regulatory factors that are naturally lost during aging.

FDA Approves VOYXACT to Treat Kidney Disease

The U.S. Food and Drug Administration (FDA) has granted accelerated approval of VOYXACT (sibeprenlimab-szsi) for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression. 

Researchers Identify How to Destroy Cells That Cause Aging

Researchers at Ben-Gurion University of the Negev in Israel have discovered a way to destroy harmful “senescent” cells that accumulate with age and increase the kind of tissue damage and inflammation that slowly causes life to end.

KEYTRUDA and KEYTRUDA QLEX Approved to Treat Adults Patients with MIBC

The U.S. Food and Drug Administration has approved KEYTRUDA and KEYTRUDA QLEX in combination with Padcev, as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

Researchers Transform Cancer Therapy to Make it 20,000 Times More Effective

Researchers re-engineered the structure of the commonly ussed chemotherapy drug 5-fluorouracil (5FU) into that of a “spherical nucleic acid” — a nanostructure that weaves the drug directly into DNA strands coating tiny spheres, making its cancer cell-killing ability 20,000 more effective, while also reducing its toxicity.